risk ovarian cancer susceptibility genes, we have chosen the candidate gene approach to compare large samples of women 4 To whom correspondence should be addressed Email: mandyS@qimr.edu.au with ovarian cancer to unaffected control subjects.
It has been suggested that increased exposure to progesterone Epidemiological studies suggest that ovarian cancer is may protect against ovarian cancer (6) . This author proposed an endocrine-related tumour, and progesterone exposure that: the 10-fold increases in maternal circulating progesterone specifically may decrease the risk of ovarian cancer. To levels may account for the additional protective aspect of assess whether the progesterone receptor (PR) exon 4 valine pregnancy beyond that attributable to suppression of ovulation; to leucine amino acid variant is associated with specific the progesterone content of the oral contraceptive (OC) pill tumour characteristics or with overall risk of ovarian may explain the large reduction in risk associated with use of cancer, we examined 551 cases of epithelial ovarian cancer OCs (including progestin-only formulations) that cannot be and 298 unaffected controls for the underlying G→T attributed to ovulation suppression alone; and that the decreased nucleotide substitution polymorphism. Stratification of the progesterone levels associated with higher levels of physical ovarian cancer cases according to tumour behaviour (low activity in premenopausal women may account for reported malignant potential or invasive), histology, grade or stage failed to reveal any heterogeneity with respect to the increasing trend in risk of ovarian cancer with increasing levels genotype defined by the PR exon 4 polymorphism. Furtherof physical activity (6) . more, the genotype distribution did not differ significantly
The action of progesterone is mediated via the progesterone between ovarian cancer cases and unaffected controls.
receptor (PR). Progesterone binds to PR, and the activated PR Compared with the GG genotype, the age-adjusted odds protein translocates to the cell nucleus under the control of ratio (95% confidence interval) for risk of ovarian cancer hinge region signals. PR-PR homodimers are formed, and was 0.78 (0.57-1.08) for the GT genotype, and 1.39 (0.47-these interact with hormone response elements of PR-respons-4.14) for the TT genotype. In conclusion, the PR exon 4 ive genes to regulate their transcription. Thus the cellular codon 660 leucine variant encoded by the T allele does not responses to progesterone are influenced by both PR protein appear to be associated with ovarian tumour behaviour, level and activity in addition to progesterone hormone levels.
histology, stage or grade. This variant is also not associated
In support of a protective effect of progesterone, cytosolic PR with an increased risk of ovarian cancer, and is unlikely concentration was observed to be significantly lower in 51 to be associated with a large decrease in ovarian cancer malignant primary epithelial ovarian tumours than in 45 benign risk, although we cannot rule out a moderate inverse ovarian tumours and 28 normal ovaries (7) , and loss of PR in association between the GT genotype and ovarian cancer.
malignant tumours appeared to be independent of oestrogen receptor loss (7) . In addition, exposure to progesterone may affect ovarian tumour characteristics: PR concentration was Introduction shown to be decreased in anaplastic tumours compared with more differentiated ones (7); high tumour PR levels have been Ovarian cancer is the sixth most common cancer among correlated with longer survival (8, 9) ; loss of heterozygosity in women (1) , and the lifetime risk of developing ovarian cancer the region of the PR locus has been associated with reduced is approximately 1 in 100 in Australian women (2) . While PR expression and reduced survival (10,11); and retention of mutations in the breast cancer susceptibility genes BRCA1 and heterozygosity in the region of the PR locus has been associated BRCA2, or in the mismatch repair genes hMSH2 and hMLH1, with endometrioid rather than serous or mucinous histology are responsible for most 'hereditary' ovarian cancers from (10,11). multiple-case families (3) , the vast majority (97%) of Australian Genes involved in progesterone metabolism and function patients with ovarian cancer present without a family history are thus putative low-risk ovarian cancer predisposition genes, of ovarian cancer in a first degree relative (4). However, results and common functional allelic variants affecting gene expression or protein function in this pathway are candidates for region Ser226Gly, Cys256Val and Thr344Ser variants, and the wild-type allele (13, 14) , with highest transcriptional activity SD 13.6 13.9
for the heterodimer receptor (13, 14) . This functional data 
Materials and methods
included in the original case-control study (4) , and it was thus not possible Subjects to use these population-based controls for genotype analysis. Control individuals from another source were utilized for genotype analysis, as described Selected characteristics of cases and controls are displayed in Table I .
Criteria for eligibility of cases (n ϭ 556) were diagnosis of primary previously (25) . Briefly, 300 unrelated adult female monozygotic twins (only one per pair) were selected from a sample of 3348 twins recruited through epithelial ovarian adenocarcinoma and availability of normal (tumour-free) tissue for extraction of germline DNA. Incident cases were ascertained during the volunteer National Australian Twin Registry for the Semi Structured Assessment for the Genetics of Alcoholism research study (26). Like cases, the period 1990-1993 via major gynaecological-oncology treatment centres in New South Wales, Victoria and Queensland as part of a large populationcontrols were almost exclusively of European descent, and were recruited from major cities in the eastern states of Australia (26). Controls were selected based case-control study (4) (n ϭ 366), and this sample was extended with a collection of incident cases ascertained during 1985-1996 from the Royal to match as closely as possible the date of birth distribution observed for (Table III) . Although age was not associated with GCG TTC CA-TAMRA-3Ј were used to detect the G and T alleles, respectively. PR genotype, ORs were adjusted for age since the mean ages
The final concentration of reagents in the PCR mix (reaction volume 25 µl) of cases and controls were significantly different (57.6 versus was 1ϫ TaqMan Universal PCR Master Mix (PE Applied Biosystems), 51.1 years; P Ͻ 0.001). The rarity of the TT genotype 900 nM primers, 100 nM FAM-G probe and 150 nM TET-T probe. Reaction mix was added to 30 ng genomic sample DNA that had been pre-dried in precluded accurate assessment of the risk associated with this 96-well plates. PCR reactions were incubated in the ABI 7700 SDS PCR genotype. There was no evidence that the PR exon 4 GT machine for 2 min at 50°C, 10 min at 95°C, followed by 45 two-step cycles genotype increased risk of ovarian cancer overall, rather this of 15 s at 95°C and 1 min at 62°C. Genotype analysis was performed on genotype was associated with a non-significant decrease in amplified samples using the ABI PRISM 7700 software, following standard procedures. Repeatability of the ABI PRISM 7700 SDS genotyping was risk to 0.78 (95% CI ϭ 0.57-1.08; P ϭ 0.1). As might be assessed by re-analysis of a sub-sample of 121 DNA samples, selected on the expected from the analysis of PR genotype heterogeneity basis of DNA availability. Successful re-amplification of samples generated shown in Table II distribution were assessed with respect to age group and parity (MantelHaenszel χ 2 test for trend), and amongst cases only with respect to oral Discussion contraceptive use, tubal ligation and hysterectomy (χ 2 test). Since the TT genotype is very rare, statistical tests for differences in genotype distribution Previous studies have suggested that progesterone exposure were performed excluding this genotype to satisfy the asymptotic assumptions for the χ 2 statistic. Logistic regression was used to calculate odds ratios (ORs) mediated via the PR may affect ovarian tumour characteristics and 95% confidence intervals (CIs) for the influence of PR exon 4 genotype (7-11), and that increased progesterone exposure may protect on risk of ovarian cancer, with adjustment for age. SPSS (version 9.0) and against the overall risk of ovarian cancer (6,7). The PROGINS Ottutil software were used for statistical analyses.
complex, including the PR exon 4 codon 660 T variant, has been reported to be associated with increased transcriptional Results activation relative to the wild-type (13, 14) . Thus, one might expect the PR exon 4 variant to be associated with specific Genotype data were generated for 551 cases (99%) and 298 controls (99%). This subset of samples did not differ tumour characteristics, and specifically with a decreased risk of ovarian cancer. Furthermore, since the PROGINS-wildsignificantly from the total sample with regard to the selected characteristics, as described in Table I , or tumour behaviour, type heterodimer was reported to be associated with the greatest transcriptional activity relative to the wild-type (13), histology, stage and grade (P ജ 0.9 for all comparisons). There was no deviation from Hardy-Weinberg equilibrium in a protective effect for the PR exon 4 T allele might be greatest for individuals who are heterozygous for this variant. cases (P ജ 0.8 for total sample, LMP or invasive tumours), or in controls (P ϭ 0.2).
However, the data presented in this study provide no evidence that the genotype defined by the PR exon 4 G→T Ovarian cancer cases were stratified by tumour behaviour, and invasive cases were further stratified by histology, grade codon 660 polymorphism is associated with tumour characteristics such as tumour behaviour, histology, grade or stage. The and stage (Table II) to investigate the possibility of PR exon study to a series of 832 younger controls collected as part of equivalent to the TT genotype) was rare (average 3 and 2.5% in cases and controls, respectively), and similar in frequency to that observed for the TT genotype in this study (2% for TT genotype occurred at a very low frequency, and thus we cases and controls). The frequency of the heterozygote Alu were unable to evaluate the effect of this genotype on ovarian insertion (purportedly equivalent to the GT genotype) was cancer risk. There was no evidence that the PR exon 4 GT 22% (range 16-34%) in cases, and 21% (range 18-25%) in genotype is associated with an increased risk of ovarian cancer. controls (15-17), compared with 26% in cases and 30% in Interestingly, the OR for the GT genotype fell below unity controls in our dataset. For the pooled sample of published (0.78), which is not inconsistent with the hypothesis that the data on the Alu insertion (15-17), there was no difference heterozygote genotype of purported greatest activity (13) would between cases and controls in the genotype frequency of the be associated with increased progesterone exposure, leading heterozygote Alu insertion compared with the wild-type to a reduction in risk of ovarian cancer. However, this decreased (P ϭ 0.9), and thus no evidence that the Alu insertion is risk was not statistically significant (95% CI ϭ 0.57-1.08; associated with either an increased or decreased risk of P ϭ 0.1). This study of 551 cases and 298 controls had 80% ovarian cancer. power at the 5% significance level to detect an OR of 0.63
In conclusion, the PR exon 4 codon 660 leucine variant (37% decrease in risk) associated with the GT genotype.
encoded by the T allele does not appear to be associated with There was no association between genotype and the ovarian ovarian tumour behaviour, histology, stage or grade. There is cancer risk factors age and parity in either cases or controls, no evidence to suggest that this variant, reported to be in indicating that confounding due to these factors was improblinkage disequilibrium with the PR intronic Alu insertion able. Confounding due to other factors such as OC use, tubal (13, 14) , increases the risk of ovarian cancer. The GT genotype ligation or hysterectomy cannot be excluded, but the absence is unlikely to be associated with a large decrease in ovarian of an association between genotype and these risk factors in cancer risk, but we cannot exclude a moderate inverse associcases suggests at least that interaction between PR genotype ation between the GT genotype and ovarian cancer, and a and OC use is unlikely, and provides some reassurance that larger study would be necessary to establish whether such an confounding is unlikely. Confounding due to differences in association exists. ethnicity was unlikely, since controls were almost exclusively of European descent (26), and the same was true for casesand selection of control-subject DNA. We are grateful to the many women 14. Kieback,D., Tong,X.-W., Weigel,N.L. and Agoulnik,I.U. (1998) A genetic mutation in the progesterone receptor (PROGINS) leads to an increased who participated in this research. 
